Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc is positioned favorably due to its innovative drug pipeline targeting unmet medical needs in oncology and COVID-19, particularly with products like Endoxifen for breast cancer and AT-H201 and AT-301 for COVID-19 treatment. The company presents an attractive current valuation, as indicated by positive net present value (NPV) assessments, which suggest significant upside potential relative to its current share price. Furthermore, anticipated key clinical milestones and data releases are expected to serve as strong catalysts for stock performance, reinforcing optimism among analysts.

Bears say

Atossa Therapeutics Inc reported a net loss of $8.7 million, an earnings per share (EPS) of $(0.07), which aligns with previous estimates but raises concerns given the company's consistent inability to improve financial performance over multiple reporting periods. The financial outlook is further compounded by significant risks including balance sheet and liquidity challenges, potential failures in clinical trials, and uncertainties surrounding regulatory approvals and commercialization efforts. Additionally, external factors such as competition, macroeconomic changes, and fluctuating investor sentiment in the biotech sector contribute to a negative outlook for the company's stock performance.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.